Source: CureToday articles
In advanced head and neck squamous cell carcinoma, evorpacept and Keytruda didn’t meet the primary endpoints of the ASPEN-03 and ASPEN trials.
Recent Content
- AAN 2025: Low-Sodium Oxybate Improves Sleep Quality, Daily Functioning in Narcolepsy, Idiopathic Hypersomnia
- Understanding the FDA Imfinzi Combo Approval for Bladder Cancer Care
- New Options for ER+ Breast Cancer Spotlighted at Patient Event
- Asembia’s AXS25 Summit: Must-See Sessions, Expert Interviews as Specialty Pharmacy Gathers
- A Digital Detox for the Soul with Lynch Syndrome
- NCPA Urges DOGE to Examine PBMs for Waste, Fraud, and Abuse
- Decipher Prostate Test Now Available for Metastatic Prostate Cancer
- Pyrotinib-Based Therapy May Improve Survival in Patients With HER2+ Breast Cancer and Liver Metastases
- Many Patients With Elevated LDL Cholesterol Are Not Prescribed Lipid-Lowering Medication
- Survey Respondents Report Dietary Modifications Help Relieve Endometriosis-Related Pain